Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer.

Area of Science:

• Oncology
• Immunotherapy
• Genetics

Background:

• Limited therapeutic options exist for oncogene-driven lung cancer patients post-tyrosine kinase inhibitor (TKI) therapy.
• Immune checkpoint inhibitor (ICI) therapy is increasingly used in lung cancer, but its role in oncogene-driven disease requires further investigation.

Purpose of the Study:

• To review current literature on ICI therapy in oncogene-driven non-small-cell lung cancer (NSCLC) after TKI progression.
• To identify challenges, potential strategies, and future research directions for improving ICI efficacy and tolerability.

Main Methods:

• Comprehensive literature review using PubMed.
• Analysis of studies evaluating ICI monotherapy, concurrent ICI and TKI therapy, and sequential ICI and TKI therapy.
• Exploration of novel patient selection methods and therapeutic combinations.

Main Results:

• ICI monotherapy shows limited efficacy and tolerability in oncogene-driven NSCLC.
• Concurrent ICI and TKI therapy is associated with increased toxicity and no significant activity increase.
• Sequential ICI therapy after TKI may reduce toxicity, but requires further study.
• Novel patient selection biomarkers (e.g., high CD8+ TILs) and combinations (e.g., with anti-VEGF or radiotherapy) show promise.

Conclusions:

• Oncogene-driven NSCLC patients progressing on TKIs face significant unmet needs.
• ICI therapy requires careful consideration regarding sequencing, patient selection, and combination strategies.
• Further research is crucial to optimize immunotherapy for this patient population.